24MAY

CEPI rescues Moderna H5N1 vaccine trial

2 min read

16:06UTC

CEPI committed $54.3m to keep Moderna's Phase 3 mRNA H5N1 vaccine trial alive after the US health department scrapped its funding.

← Back to Ebola triples, response misfires Jump to analysis ↓

ScienceDeveloping

Key takeaway

CEPI is now funding the leading bird-flu vaccine trial that US federal money abandoned mid-stream.

The Coalition for Epidemic Preparedness Innovations (CEPI) committed $54.3 million to keep alive Moderna's Phase 3 trial of its messenger-RNA (mRNA) H5N1 vaccine after the US Department of Health and Human Services scrapped the federal funding⁠¹. First participants were dosed on 21 April, and the candidate, mRNA-1018, is the furthest any mRNA H5N1 vaccine has reached⁠². H5N1 is the avian influenza strain whose spread through dairy cattle and poultry has kept pandemic planners watching.

The rescue is the same retreat-and-backstop pattern visible at the US border and in the thinned-out Ituri response: a US withdrawal from a pandemic-preparedness commitment, absorbed by a multilateral body. CEPI did not fund this trial originally; it stepped into a gap created by a policy decision, which leaves the world's leading bird-flu vaccine candidate dependent on whoever is willing to cover the cost after the largest single funder leaves.

Deep Analysis

In plain English

H5N1 is the bird flu strain that has been spreading in US dairy cattle since 2024. Scientists have long worried that if it mutates to spread easily between people, it could cause a severe pandemic. Moderna, a US vaccine company, developed an mRNA-based H5N1 vaccine candidate called mRNA-1018 using the same technology platform as the Covid-19 vaccines. It is now in Phase 3, the large-scale human trial that tests whether a vaccine is safe and effective before it can be approved. CEPI, the Coalition for Epidemic Preparedness Innovations (a global partnership funded by governments and charities), committed $54.3 million to keep the trial running after the US government's health department pulled its funding. First participants were dosed on 21 April 2026. This trial matters because if H5N1 did cause a human pandemic, an already-tested mRNA vaccine could be adapted and produced far faster than a traditional egg-based vaccine.

Source Landscape

This story draws on neutral-leaning sources

Consensus view: CEPI's 100 Days Mission framework, which aims to have a vaccine in Phase 3 trial within 100 days of a declared pandemic threat, is being tested in real time by the mRNA-1018 commitment: CEPI's $54.3 million fills the gap left by HHS withdrawing US government funding, but the dependency is now on a single Coalition funder rather than the distributed public-private architecture that produced COVID-19 vaccines at speed.

First dosing on 21 April and Phase 3 continuation to completion represents the furthest any mRNA H5N1 candidate has reached.

Counter-view: The Pasteur Network's regulatory capacity programme, which CEPI expanded via a 21 April 2026 partnership, argued that the mRNA-1018 trial's value is contingent on regulatory capacity in potential pandemic-affected countries: if H5N1 achieves efficient human-to-human transmission in Southeast Asia or Latin America, those countries' regulatory agencies would need expedited review pathways to authorise the vaccine for emergency use.

Those pathways still do not exist in most middle-income countries, regardless of how fast CEPI can manufacture doses.

Key tension: Whether a Phase 3 trial result obtained under CEPI funding, without US government co-ownership, can be leveraged into rapid FDA Emergency Use Authorisation and simultaneous WHO Emergency Use Listing: the two regulatory gates that would determine actual deployment speed in a pandemic.

Sources:Coalition for Epidemic Preparedness Innovations

Mentions:H5N1 →United States →Phase 3 →Pasteur Network →Coalition →Washington →World Health Organization →Moderna →CEPI →100 Days Mission →Emergency Use Listing →

First Reported In

Update #4 · Ebola triples, response misfires

Coalition for Epidemic Preparedness Innovations· 24 May 2026

Read original →

Causes and effects

Caused by

Moderna begins Phase 3 H5N1 mRNA trial

CEPI's $54.3m commitment rescues the Moderna Phase 3 trial that began dosing on 22 April after CEPI's original announcement.

Occurred 22 Apr 2026

Read story →

This Event

CEPI rescues Moderna H5N1 vaccine trial

A multilateral coalition is now financing the furthest-advanced bird-flu vaccine that Washington walked away from.

Different Perspectives

IGWG co-chair Tovar da Silva Nunes

The Brazilian co-chair closed the eighth pathogen-sharing session on 18 September without an agreed annex text, the second session in a row to end that way. He presented the outcome as continued commitment, with adoption due at the World Health Assembly in May 2027.

Fraport

The Frankfurt Airport operator has told staff to watch for fever, hessenschau reported, after six airport workers caught malaria. Germany does not require insecticide spraying of arriving aircraft cabins, and parasite genotyping to trace the source is due at the end of October.

European Centre for Disease Prevention and Control

ECDC reported the eight Frankfurt Airport malaria cases on 18 September and considers repeated arrivals of infected mosquitoes on aircraft likely. It has not ruled out local mosquitoes, and awaits genotyping due at the end of October.

Pan American Health Organization

PAHO counted 53,957 measles cases in the Americas by 19 September and is supporting Peru's response in Puno and Arequipa. It warns that October's Señor de los Milagros festivities and Pope Leo XIV's November visit could increase transmission.

Bangladesh Directorate General of Health Services

The DGHS recorded 1,030 measles-related deaths and 172,720 suspected cases by 14 September, after a campaign that reached 19.75 million children. Its disease-control director, Halimur Rashid, said further vaccination rounds were expected within two weeks.

Minapharm

The Egyptian drugmaker and its Berlin subsidiary ProBioGen were awarded up to US$16.5m by CEPI on 27 August to take a Bundibugyo vaccine into a Phase 1 trial in Africa. Final manufacture is planned for Cairo, making it CEPI's first Bundibugyo candidate with an African producer.